Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zurdo who wrote (4916)	8/13/1998 11:02:00 AM
From: Dave	Read Replies (1) \| Respond to of 9523

Zurdo, <<I don't know what big run up you are talking about...If there was one, it has vanished over the last several weeks>> PFE was in the low $50 range last year in August. That's a pretty good runup even if it's down from its recent high. The market is also down and PFE does move with the market. <<Your stated philosophy of this being an investor's stock rather than a trader's stock seems to be reversed>> I definitely would not consider the big Pharmas to be trading stocks. I guess one can trade any stock but compared with the internet stocks for example, the big Pharmas are relatively non-volatile. Look at PFE % changes, both intra-day and inter-day and you will see that the opportunity for making large % gains in comparison with other stocks such as the techs are usually smaller. That's why I don't consider it to be a day trading stock. I do agree with you that PFE options are probably a good play - especially the longer term ones and the LEAPS. As far as manipulation goes,it is really hard for us small individual investors to beat the big guys when it comes to day to day trading and pricing on options. I really do believe that a buy and hold strategy is our best bet. I have been burned too many times trying to time stocks and day trade. I wish you the best of luck and hope that PFE brings you what you are looking for. Regards, Dave